Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly ...
Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...
Investor's Business Daily on MSN13m
Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial ResultsNovo Nordisk reported strong early-stage results for its once-a-week obesity drug. Early Friday, Novo Nordisk stock jumped. Eli Lilly fell.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback